Phase 2 obesity trial (NEJM, 2023), retatrutide produced a mean body-weight reduction of up to 24.2% at 48 weeks in the highest-dose cohort, following a 2 mg starting dose escalated every four weeks to 12 mg weekly [1][2]
Insulin Resistance and Diabetes. GLP-1 and metabolism: Frontiers in Endocrinology (2021)
Skin Brightening & Glow Reduces hyperpigmentation, promotes even skin tone, and delivers a luminous complexion from within
20
The 48-week study tracked weight loss, metabolic markers, and adverse events
[146] Dependence and withdrawal Drug tolerance develops rapidly in amphetamine abuse (i.e., recreational amphetamine use), so periods of extended abuse require increasingly larger doses of the drug in order to achieve the same effect